Key result
SGLT2 inhibitors linked to ~60% improvement in health status and quality of life in HFrEF.
Why the study?
The impact of SGLT2 inhibitors on patient-reported quality of life required further evaluation, particularly in the Indian population.
Does dapagliflozin improve patient-reported health status (KCCQ-12 scores) in patients with symptomatic HFrEF?
Does dapagliflozin improve patient-reported health status (KCCQ-12 scores) in patients with symptomatic HFrEF?
Answers are grounded in this paper and cite their sources.
Dapagliflozin added to standard care significantly improves patient-reported health status, symptom burden, and quality of life in Indian patients with symptomatic HFrEF.
Heart failure with reduced ejection fraction (HFrEF) remains a major public health challenge, leading to significant morbidity and mortality. The Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) is a validated tool for assessing the health status of heart failure patients. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapeutic approach, improving cardiovascular outcomes. However, their impact on patient-reported quality of life needs further evaluation, especially in the Indian population. Objective: To evaluate the health status of patients with symptomatic HFrEF receiving SGLT2 inhibitors using KCCQ-12, focusing on improvements in physical limitations, symptom frequency, quality of life, and social limitations. Methods: A prospective case-control study was conducted at GSVM Medical College, Kanpur, over two years. A total of 84 patients with HFrEF were enrolled and assessed at three visits: baseline (Visit 1), after one month of standard care (Visit 2), and after six months of SGLT2 inhibitor therapy (Visit 3). KCCQ-12 domain scores were analysed using paired t-tests and Wilcoxon signed-rank tests. Results: Significant improvements were observed in all KCCQ-12 domains Domains V1 →V2 (%) V2 → V3 (%) Cumulative V1 → V3 (%) SS 31.1 17.5 60.4 SF 31.1 17.6 60.4 PL 31.1 17.6 60.4 SL 31.0 17.7 60.2 QL 31.1 17.6 60.4 Improvement Patterns Visit 1→2: Consistent ~31% improvement across all domains, reflecting strong initial treatment response. Visit 2→3: ~17.6% further gains, showing continued but slower progression. SF/PL equivalence: Identical trajectories confirm these domains measure overlapping constructs in this cohort. Total cumulative improvement from Visit 1 to 3 ranged 54-62% across domains, with paired t-tests confirming statistical significance (p<0.0001) for both intervals. This result correlating with improved functional and symptomatic status. Conclusion: SGLT2 inhibitors significantly enhance the quality of life, reduce symptom burden, and improve functional capacity in patients with HFrEF, as measured by KCCQ-12. These findings reinforce their role as an essential therapy in heart failure management.
No takes yet. Share an insight, caveat, or question.
International Journal of Medical Science and Innovative Research (IJMSIR) (2025) studied this question. SGLT2 inhibitors led to a cumulative improvement of 60.4% in health status among patients with HFrEF, significantly enhancing quality of life and reducing symptom burden.
Synapse has enriched 10 related papers. Consider them for comparative context: